⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1857059 | 0.88 | — | — | |
| SCHEMBL1856408 | 0.78 | — | — | |
| SCHEMBL16051779 | 0.71 | — | — | |
| SCHEMBL2778317 | 0.67 | — | — | |
| SCHEMBL20610588 | 0.65 | — | — | |
| SCHEMBL1855995 | 0.65 | — | — | |
| SCHEMBL166539 | 0.63 | — | — | |
| SCHEMBL5822827 | 0.62 | — | — | |
| SCHEMBL5056982 | 0.62 | — | — | |
| SCHEMBL13834868 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11752138-B2 | Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase | VANDERBILT UNIVERSITY (US) | 2023-09-12 | — | — | US | claimed |
| US-20210369683-A1 | TREATING PRIMARY OR IDIOPATHIC HYPEROXALURIA WITH SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-12-02 | — | — | US | claimed |
| US-10954228-B2 | 1 H-pyrazol-1-yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2021-03-23 | — | — | US | claimed |
| US-20190276448-A1 | 1 H-PYRAZOL-1-YL-THIAZOLES AS INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | THE UAB RESEARCH FOUNDATION | 2019-09-12 | — | — | US | claimed |
| EP-3478677-A1 | 1 H-PYRAZOL-1 -YL-THIAZOLES AS INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2019-05-08 | — | — | EP | claimed |
| WO-2018005807-A1 | 1 H-PYRAZOL-1 -YL-THIAZOLES AS INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-01-04 | — | — | WO | claimed |
| US-8895584-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-25 | — | — | US | claimed |
| US-20140243382-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-28 | — | — | US | claimed |
| US-8759347-B2 | Inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | claimed |
| US-20130281475-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-24 | — | — | US | claimed |
| US-8481564-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-07-09 | — | — | US | claimed |
| US-20110195960-A1 | INHIBITORS OF C-FMS KINASE | ILLIG CARL R | 2011-08-11 | — | — | US | claimed |
| US-7973035-B2 | Inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-07-05 | — | — | US | claimed |
| EP-2021335-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-25 | — | — | EP | claimed |
| EP-2021335-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE | Janssen Pharmaceutica, N.V. (BE) | 2009-02-11 | — | — | EP | claimed |
| US-20080275031-A1 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | ILLIG CARL R | 2008-11-06 | — | — | US | claimed |
| US-7414050-B2 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-19 | — | — | US | claimed |
| WO-2007124316-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | claimed |
| US-20070249593-A1 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | claimed |
| US-12030869-B2 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2024140824-A1 | PYRIDAZINE NLRP3 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 长春金赛药业有限责任公司 | 2024-07-04 | — | — | WO | disclosed |
| US-20240150324-A1 | 5-Membered Heteroaryl Carboxamide Compounds for Treatment of HBV | ASSEMBLY BIOSCIENCES, INC. | 2024-05-09 | — | — | US | disclosed |
| WO-2024067675-A1 | FUSED RING KIF18A INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 长春金赛药业有限责任公司 | 2024-04-04 | — | — | WO | disclosed |
| WO-2024051755-A1 | KIF18A INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR AND USE THEREOF | 长春金赛药业有限责任公司 | 2024-03-14 | — | — | WO | disclosed |
| US-20230372308-A1 | TREATING PRIMARY OR IDIOPATHIC HYPEROXALURIA WITH SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE | VANDERBILT UNIVERSITY | 2023-11-23 | — | — | US | disclosed |
| US-20230295096-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-11752138-B2 | Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase | VANDERBILT UNIVERSITY (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230183213-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230075856-A1 | CYCLIC SULFAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES INC (US) | 2023-03-09 | — | — | US | disclosed |
| EP-4139000-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | Assembly Biosciences, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-4139292-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | Assembly Biosciences, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| US-11560370-B1 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210369683-A1 | TREATING PRIMARY OR IDIOPATHIC HYPEROXALURIA WITH SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-12-02 | — | — | US | disclosed |
| WO-2021216642-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021216660-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021216661-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021216656-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| EP-3846820-A1 | CYCLIC SULFAMIDE COMPOUNDS FOR TREATMENT OF HBV | Assembly Biosciences, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-10954228-B2 | 1 H-pyrazol-1-yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2021-03-23 | — | — | US | disclosed |
| US-20190276448-A1 | 1 H-PYRAZOL-1-YL-THIAZOLES AS INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | THE UAB RESEARCH FOUNDATION | 2019-09-12 | — | — | US | disclosed |
| EP-3478677-A1 | 1 H-PYRAZOL-1 -YL-THIAZOLES AS INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2019-05-08 | — | — | EP | disclosed |
| WO-2018005807-A1 | 1 H-PYRAZOL-1 -YL-THIAZOLES AS INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-01-04 | — | — | WO | disclosed |
| US-9452996-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-27 | — | — | US | disclosed |
| US-9403804-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-02 | — | — | US | disclosed |
| US-9394289-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-19 | — | — | US | disclosed |
| US-20160122334-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-05-05 | — | — | US | disclosed |
| US-9296726-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-29 | — | — | US | disclosed |
| US-9266866-B2 | Inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-23 | — | — | US | disclosed |
| US-20160046602-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-18 | — | — | US | disclosed |
| EP-2016070-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-13 | — | — | EP | disclosed |
| EP-2016074-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-13 | — | — | EP | disclosed |
| EP-2016058-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-06 | — | — | EP | disclosed |
| US-9221797-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-29 | — | — | US | disclosed |
| US-20150051196-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-19 | — | — | US | disclosed |
| US-20140378457-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-25 | — | — | US | disclosed |
| US-8895584-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-25 | — | — | US | disclosed |
| US-20140329815-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-06 | — | — | US | disclosed |
| US-8859602-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-14 | — | — | US | disclosed |
| US-20140243382-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-28 | — | — | US | disclosed |
| US-8815867-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-26 | — | — | US | disclosed |
| US-20140200245-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-17 | — | — | US | disclosed |
| US-8759347-B2 | Inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | disclosed |
| US-20140148448-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-29 | — | — | US | disclosed |
| US-8722718-B2 | Inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-13 | — | — | US | disclosed |
| US-8674100-B2 | Inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2014-03-18 | — | — | US | disclosed |
| EP-2687516-A1 | Inhibitors of C-FMS Kinase | Janssen Pharmaceutica N.V. (BE) | 2014-01-22 | — | — | EP | disclosed |
| US-20130281475-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-24 | — | — | US | disclosed |
| EP-2631238-A1 | Spirocyclic inhibitors of serine proteases for the treatment of hcv infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8481564-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-07-09 | — | — | US | disclosed |
| US-20130131356-A1 | PREPARATION OF PROTECTED ALPHA-KETO BETA-AMINO ESTERS AND AMIDES | VERTEX PHAMACEUTICALS INCORPORATED (US) | 2013-05-23 | — | — | US | disclosed |
| US-8378124-B2 | Preparation of protected alpha-keto beta-amino esters and amides | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-19 | — | — | US | disclosed |
| US-8372873-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-20110213161-A1 | Preparation of Protected Alpha-Keto Beta-Amino Esters and Amides | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110195960-A1 | INHIBITORS OF C-FMS KINASE | ILLIG CARL R | 2011-08-11 | — | — | US | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-7973035-B2 | Inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-07-05 | — | — | US | disclosed |
| US-7964624-B1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2021335-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-25 | — | — | EP | disclosed |
| EP-2303858-A1 | PREPARATION OF PROTECTED ALPHA-KETO BETA-AMINO ESTERS AND AMIDES | Vertex Pharmceuticals Incorporated (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010002474-A1 | PREPARATION OF PROTECTED ALPHA-KETO BETA-AMINO ESTERS AND AMIDES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-07 | — | — | WO | disclosed |
| EP-2114958-A1 | INHIBITORS OF SERINE PROTEASES FOR THE TREATMENT OF HCV INFECTIONS | Vertex Pharmceuticals Incorporated (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-2021329-A1 | INHIBITORS OF C-FMS KINASE | Janssen Pharmaceutica, N.V. (BE) | 2009-02-11 | — | — | EP | disclosed |
| EP-2021335-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE | Janssen Pharmaceutica, N.V. (BE) | 2009-02-11 | — | — | EP | disclosed |
| EP-2016074-A1 | INHIBITORS OF C-FMS KINASE | Janssen Pharmaceutica, N.V. (BE) | 2009-01-21 | — | — | EP | disclosed |
| EP-2016058-A1 | INHIBITORS OF C-FMS KINASE | Janssen Pharmaceutica, N.V. (BE) | 2009-01-21 | — | — | EP | disclosed |
| EP-2016070-A1 | INHIBITORS OF C-FMS KINASE | Janssen Pharmaceutica, N.V. (BE) | 2009-01-21 | — | — | EP | disclosed |
| WO-2009009059-A1 | SPIRO COMPOUNDS AS ANTAGONISTS OF TGF-BETA | BIOGEN IDEC MA INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20080275031-A1 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | ILLIG CARL R | 2008-11-06 | — | — | US | disclosed |
| WO-2008106139-A1 | INHIBITORS OF SERINE PROTEASES FOR THE TREATMENT OF HCV INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-04 | — | — | WO | disclosed |
| US-7414050-B2 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-19 | — | — | US | disclosed |
| WO-2007124319-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007124321-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007124322-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007124318-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007124316-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249608-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249608-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249649-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249685-A1 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249593-A1 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249680-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |